ClinicalTrials.gg

Program

Finasteride

Also written as “Finasteride 5 mg Tablet, single dose”, “minoxidil + finasteride” and “Finasteride 5 mg tablets”.

Its studies are mostly in Alopecia · Prostatic Hyperplasia · Acne Vulgaris, led by 9 companies.

Furthest: phase 3, since May 27, 201017 company-led studies, 1 open or runningNext primary completion: Aug 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dr. Reddy's Laboratories40 open or runningphase 1since May 27, 2010May 27, 2010none ahead
Teva Pharmaceutical Industries40 open or runningphase 1since Feb 3, 2009Feb 3, 2009none ahead
Il-Yang Pharm.21 open or runningphase 3since Oct 6, 2026Dec 11, 2025Aug 31, 2027phase 3 · NCT07870759
Viatris20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Almirall10 open or runningphase 1since Jun 1, 2016Jun 1, 2016none ahead
Beijing Dayspring Pharmaceutical Technology10 open or runningphase 2since Jul 1, 2025Jul 1, 2025none ahead
Elorac10 open or runningphase 2since Jul 10, 2015Jul 10, 2015none ahead
HairDx10 open or runningphase 1since Jan 16, 2010Jan 16, 2010none ahead
Merck10 open or runningphase 3since Feb 13, 2012Feb 13, 2012none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 30, 2008First studies: 2 phase 1 studies in HealthyNew to ViatrisViatris · NCT00650377, NCT00648791
  2. Feb 3, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00835796, NCT00835666
  3. Mar 26, 20092 phase 1 studies in HealthyTeva Pharmaceutical Industries · NCT00871247, NCT00870480
  4. Jan 16, 2010HairDx's first study: phase 1 study in AlopeciaNew to HairDxHairDx · NCT01052870 · 12 enrolled
  5. May 27, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01133457, NCT01133444
  6. Dec 20, 20102 phase 1 studies in HealthyDr. Reddy's Laboratories · NCT01264302, NCT01264289
  7. Feb 13, 2012Merck's first study: phase 3 study in Prostatic HyperplasiaNew to MerckMerck · NCT01534351 · 1 enrolled
  8. Jul 10, 2015Elorac's first study: phase 2 study in Acne VulgarisNew to EloracElorac · NCT02502669 · 106 enrolled · United States
  9. Jun 1, 2016Almirall's first study: phase 1 study in AlopeciaNew to AlmirallAlmirall · NCT02791243 · 58 enrolled · United Kingdom
  10. Jul 1, 2025Beijing Dayspring Pharmaceutical Technology's first study: phase 2 study in AlopeciaNew to Beijing Dayspring Pharmaceutical TechnologyBeijing Dayspring Pharmaceutical Technology · NCT07076706 · 110 enrolled · China
  11. Dec 11, 2025Il-Yang Pharm.'s first study: phase 1 study in Healthy Adult MaleNew to Il-Yang Pharm.Il-Yang Pharm. · NCT07322991 · 43 enrolled · South Korea
  12. Oct 6, 2026Phase 3 study in Prostatic HyperplasiaPhase 3 reachedIl-Yang Pharm. · NCT07870759 · 660 planned

Ahead

  1. Aug 31, 2027Primary completion: phase 3 study in Prostatic HyperplasiaIl-Yang Pharm. · NCT07870759

TargetBeta

SRD5A2 →read by rule
“Steroid 5-alpha-reductase 2 inhibitor”ChEMBL 37, by rule

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07870759Prostatic Hyperplasia3Not yet recruitingIl-Yang Pharm.Aug 31, 2027660
NCT07322991Healthy Adult Male · South Korea1CompletedIl-Yang Pharm.Dec 1, 202543
NCT07076706Alopecia · China2CompletedBeijing Dayspring Pharmaceutical TechnologyAug 26, 2025110
NCT02791243Alopecia · United Kingdom1CompletedAlmirallJun 201658
NCT02502669Acne Vulgaris · United States2CompletedEloracJun 6, 2017106
NCT01534351Prostatic Hyperplasia3TerminatedMerckNov 18, 20131
NCT01264302Healthy · United States1CompletedDr. Reddy's LaboratoriesNov 200626
NCT01264289Healthy · United States1CompletedDr. Reddy's LaboratoriesNov 200626
NCT01133457Healthy · Canada1CompletedDr. Reddy's LaboratoriesMay 200224
NCT01133444Healthy · Canada1CompletedDr. Reddy's LaboratoriesApr 200224
NCT01052870Alopecia1CompletedHairDxDec 200912
NCT00871247Healthy · Canada1CompletedTeva Pharmaceutical IndustriesNov 200426
NCT00870480Healthy · Canada1CompletedTeva Pharmaceutical IndustriesNov 200426
NCT00835796Healthy · United States1CompletedTeva Pharmaceutical IndustriesJul 200220
NCT00835666Healthy · United States1CompletedTeva Pharmaceutical IndustriesJun 200232
NCT00650377Healthy · United States1CompletedViatrisOct 200430
NCT00648791Healthy · United States1CompletedViatrisOct 200429

How it is read

Names in the registry

  • “Finasteride”, 6 entries
  • “Finasteride 5 mg Tablet, single dose”, 3 entries
  • “minoxidil + finasteride”, 2 entries
  • “Finasteride 5 mg tablets”, 2 entries
  • “Finasteride Tablets 5 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.